Core Viewpoint - The article highlights the contributions of Chinese technology professionals in various fields such as integrated circuits, artificial intelligence, and biomedicine, emphasizing their role in advancing China's technological independence and innovation [1][4][6]. Group 1: Integrated Circuits - The chairman of Loongson Technology, Hu Weiwu, emphasizes the importance of developing core technologies through persistent effort, stating that there are no shortcuts and that one must steadily pursue progress [4][6]. - In 2020, Loongson launched its fully autonomous LoongArch architecture, marking a significant step in building China's independent information system [6]. Group 2: Space Exploration - Aerospace designer Jia Yang shares the story of the Zhurong Mars rover, which was designed to navigate challenging terrains and extreme temperatures, showcasing innovative engineering solutions [7][9]. - Jia emphasizes the joy of exploration and the integration of personal passion with professional work, reflecting on his two-decade journey in deep space exploration [9]. Group 3: Artificial Intelligence - Wang Shaolan, president of Zhiyuan Technology, discusses the development of large AI models, stressing the importance of mastering key technologies domestically, especially after facing external restrictions [11][13]. - The team has successfully released a trillion-parameter model and made it open-source, breaking through foreign architectural barriers [13]. Group 4: Pharmaceutical Innovation - Sun Yinghui, deputy general manager of Shouyao Holdings, focuses on the challenges of making innovative drugs accessible, particularly in the field of lung cancer treatment [15]. - She highlights the responsibility of researchers in developing drugs that can significantly impact patients' lives, emphasizing the need for precision in treatment [15]. Group 5: Automotive Industry - Xiaomi engineer Fang Kan reflects on the challenges faced by the Chinese automotive industry, particularly in developing small molecule targeted drugs and electric vehicles [16][19]. - He shares the story of Xiaomi's journey in car manufacturing, illustrating the importance of perseverance and innovation in overcoming obstacles [19][21]. Group 6: Telecommunications - Sun Lixin, CEO of Baicai Technology, recounts the evolution of China's telecommunications from reliance on foreign technology to leading in 5G and 6G standards [21][23]. - He attributes this progress to the dedication and efforts of generations of telecommunications professionals, showcasing the collective capability to achieve significant advancements [23].

Group 1 - The core stock price of Shouyao Holdings (688197) closed at 35.3 yuan on December 26, 2025, down 4.7% from the previous week's closing price of 37.04 yuan [1] - The stock reached a weekly high of 37.55 yuan on December 22 and a low of 35.2 yuan on December 26 [1] - The current total market capitalization of Shouyao Holdings is 5.25 billion yuan, ranking 97th out of 151 in the chemical pharmaceutical sector and 3231st out of 5178 in the A-share market [1] Group 2 - Shouyao Holdings recently received a government subsidy of 60 million yuan, classified as a revenue-related government grant [2] - The company will recognize this subsidy according to the relevant accounting standards, and the specific accounting treatment and impact on the company's financial results will be confirmed by the annual audit [2]

Core Viewpoint - Shouyao Holdings (688197.SH) is currently experiencing a decline in stock price, closing at 35.30 yuan with a drop of 4.13%, indicating it is in a state of underperformance since its IPO [1] Group 1: Company Financials - Shouyao Holdings was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 23, 2022, with an initial offering price of 39.90 yuan per share and a total of 37.18 million shares issued, representing 25% of the post-issue total share capital [1] - The total funds raised during the IPO amounted to 1.483 billion yuan, with a net amount of 1.374 billion yuan after deducting issuance costs [1] - The company reported a revenue of 2 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 47.37%, and a net loss attributable to shareholders of 155 million yuan [1] Group 2: Historical Performance - Shouyao Holdings has faced continuous losses over recent years, with net profits attributable to shareholders recorded as -144.9 million yuan in 2021, -173.8 million yuan in 2022, -185.6 million yuan in 2023, and projected at -211.9 million yuan for 2024 [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, has also shown a downward trend, with figures of -162.6 million yuan in 2021, -199 million yuan in 2022, -199.4 million yuan in 2023, and an expected -235 million yuan in 2024 [2]

《首药控股（北京）股份有限公司关于获得政府补助的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 最新公告列表 截至2025年12月24日收盘，首药控股（688197）报收于36.78元，较前一交易日上涨0.25%，最新总市值 为54.7亿元。该股当日开盘36.66元，最高36.93元，最低36.4元，成交额达1873.37万元，换手率为 0.8%。 公司近日发布公告称，首药控股（北京）股份有限公司于近日收到政府补助款项6,000.00万元，属于与 收益相关的政府补助。公司根据《企业会计准则第16号——政府补助》等相关规定，确认上述事项并划 分补助类型。该补助未经审计，具体会计处理及对公司相关年度损益的影响以审计机构年度审计确认结 果为准。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：688197 证券简称：首药控股 公告编号：2025-031 首药控股（北京）股份有限公司 关于获得政府补助的公告 首药控股（北京）股份有限公司董事会 2025年12月25日 首药控股（北京）股份有限公司（以下简称"公司"）于近日收到政府补 助款项6,000.00万元，属于与收益相关的政府补助款项。 公司根据《企业会计准则第16号——政府补助》等相关规定，确认上述事 项并划分补助类型。上述政府补助未经审计，具体的会计处理以及对公司相关 年度损益的影响情况仍须以审计机构年度审计确认后的结果为准，敬请广大投 资者注意投资风险。 特此公告。 ...

Group 1 - The company, Shouyao Holdings, announced on December 24 that it has received a government subsidy of 60 million yuan, which is classified as a revenue-related government subsidy [1]

Core Viewpoint - The company, Shouyao Holdings (688197), is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its core competitiveness and brand influence, while optimizing its capital structure and diversifying financing channels [1] Group 1 - The company is currently in discussions with intermediaries regarding the specific progress of the H-share listing [1] - The details of the H-share listing have not yet been finalized [1] - The H-share listing will not result in any changes to the company's controlling shareholder or actual controller [1]

Group 1 - Moer Thread plans to use up to 7.5 billion yuan of idle raised funds for cash management, with a usage period of 12 months [1] - O-film plans to purchase 8.46% equity of its subsidiary Anhui Che Lian for a total of 3.64 billion yuan, increasing its ownership from 78.54% to 87% [2] - ST Lian Shi applies to revoke the delisting risk warning as its restructuring plan has been completed [3] Group 2 - Weirli signs a strategic cooperation framework agreement with Primech Holdings to build an industrial robot cooperation platform [4] - Race Intelligent plans to raise no more than 1.144 billion yuan through a private placement for core components of intelligent equipment [5] - Renfu Pharmaceutical's stock will be subject to other risk warnings and will be suspended for one day starting December 15 [6] Group 3 - Yongding Co. clarifies that its subsidiary Dongbu Superconductor does not directly manufacture controllable nuclear fusion devices [7] - Rongbai Technology plans to acquire part of Guizhou Xinren's equity and increase its capital to achieve control [9] - ST Hu Ke is under investigation by the Securities Regulatory Commission for suspected information disclosure violations [10] Group 4 - Yunnan Ge Industry plans to establish a subsidiary focused on organic germanium-related products [11] - Greenme intends to acquire 16.38% equity of Henan Recycling Group for 400 million yuan [12] - Jiangzhong Pharmaceutical plans to change its name to China Resources Jiangzhong Pharmaceutical [13] Group 5 - Jiangsu Guoxin's subsidiary Ma Zhou Power has completed the trial operation of a 1,000 MW coal-fired power generation unit [16] - Longsheng Technology plans to invest in a center for embodied intelligent robots [18] - Guangzhou Development has received approval for the registration of 8 billion yuan medium-term notes and 6 billion yuan short-term financing notes [19] Group 6 - China Merchants Port reported a container throughput of 17.248 million TEUs in November, a year-on-year increase of 6.4% [20] - Tianma Technology reported a total eel output of approximately 11,415.87 tons from January to November [21] Group 7 - Xilong Science plans to reduce its stake by up to 1% [22] - Xicet Testing's actual controller plans to transfer 5% of the company's shares [23] - Oppein Home's actual controller plans to increase its stake by 50 million to 100 million yuan [24] Group 8 - Maide Medical plans to repurchase shares worth 20 million to 40 million yuan [25] - Baicheng Pharmaceutical's major shareholder increased its stake by 0.85% [26] - Mengbaihe's major shareholder plans to reduce its stake by up to 1% [27] Group 9 - Xian Dao Ji Dian's shareholder has reduced its stake by 1.70% [28] - Yaxiang Integration's shareholder reduced its stake by 41,400 shares [29] - Zhiwei Intelligent's actual controller has reduced its stake, bringing the total holding to 69% [30] Group 10 - Jincheng Co.'s actual controller plans to reduce its stake by up to 0.97% [31] - Jianghua Micro's chairman has reduced his stake by 1.09% [32] - COSCO Shipping Energy signed a shipbuilding contract worth 7.882 billion yuan [33] Group 11 - Dayu Water Saving's subsidiary is expected to win two high-standard farmland construction projects [34] - Guorui Technology's subsidiary is a candidate for the GXLF project [36] - ST Zhisheng has won a smart city governance project worth 104 million yuan [37]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

智通财经APP讯，首药控股(688197.SH)发布公告，公司为进一步提升核心竞争力与品牌影响力，充分 借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，正在筹划发行境外股份(H 股)并在香港联合交易所有限公司(以下简称"香港联交所")上市事宜。 ...